FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.